Noncatalytic Bruton's tyrosine kinase activates PLC?(2) variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells

Erstveröffentlichung
2020Authors
Wist, Martin
Meier, Laura
Gutman, Orit
Haas, Jennifer
Endres, Sascha
Wissenschaftlicher Artikel
Published in
Journal of Biological Chemistry ; 295 (2020), 17. - S. 5717-5736. - ISSN 0021-9258. - eISSN 1083-351X
Link to publication
https://dx.doi.org/10.1074/jbc.RA119.011946Faculties
Medizinische FakultätInstitutions
UKU. Institut für Pharmakologie und ToxikologieMassenspektrometrie und Proteomics
UKU. Klinik für Innere Medizin III
UKU. Institut für Immunologie
Subject headings
[Free subject headings]: calcium | drug resistance | phospholipase C | phosphoinositide | inositol phospholipid | inositol phosphate | Rac (Rac GTPase) | tyrosine?protein kinase (tyrosine kinase) | B-cell receptor (BCR) | B-cell signaling | Bruton's tyrosine kinase (BTK) | chronic lymphocytic leukemia (CLL) | ibrutinib | PHOSPHOLIPASE-C-GAMMA | LIPID RAFTS | PHOSPHORYLATION SITES | C-BETA(2) ACTIVITY | CALCIUM-RELEASE | RECEPTOR | BTK | C-GAMMA(2) | BLNK | MUTATIONS[DDC subject group]: DDC 570 / Life sciences